Chronic Obstructive Pulmonary Disease News and Research RSS Feed - Chronic Obstructive Pulmonary Disease News and Research

The World Health Organisation (WHO) has described Chronic Obstructive Pulmonary Disorder (COPD) as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.
Despite increased life expectancy, British people suffer from more medical ailments

Despite increased life expectancy, British people suffer from more medical ailments

People in the UK are living longer but are coping with more medical ailments causing illness or disability in their older years, according to a major new international study published in The Lancet today (Thursday 27 August). [More]
ieCrowd announces achievement of major milestone in commercial development of Smart Oxygen device

ieCrowd announces achievement of major milestone in commercial development of Smart Oxygen device

ieCrowd today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions, automatically adjusts to a patient's changing demand for oxygen based on level of activity. [More]
Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Clementia Pharmaceuticals, Inc. today announced the initiation of enrollment of children as young as 6 years old in the company's ongoing Phase 2 study of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
U-M microbiome research may lead to new ways to prevent, fight lung infections in patients

U-M microbiome research may lead to new ways to prevent, fight lung infections in patients

With every breath you take, microbes have a chance of making it into your lungs. But what happens when they get there? And why do dangerous lung infections like pneumonia happen in some people, but not others? Researchers at the University of Michigan Medical School have started to answer these questions by studying the microbiome of the lungs - the community of microscopic organisms that are in constant contact with our respiratory system. [More]
New OTEMTO phase three results show potential improvement to quality of life for COPD patients

New OTEMTO phase three results show potential improvement to quality of life for COPD patients

Boehringer Ingelheim announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto® Respimat® (tiotropium/olodaterol) provides consistent, clinically meaningful improvements in quality of life versus placebo in patients with COPD [More]
Psychological disorders in COPD patients predict early hospital readmission

Psychological disorders in COPD patients predict early hospital readmission

Researchers from The University of Texas Medical Branch at Galveston found that people with a psychological condition such as depression, anxiety, psychosis, or alcohol/drug abuse are more likely to be readmitted early into a hospital for complications of chronic obstructive pulmonary disease. [More]
New health care program covered by Medicaid improves some aspects of care for disabled adults

New health care program covered by Medicaid improves some aspects of care for disabled adults

UF Health researchers have found that care linked to heart attacks and chronic obstructive pulmonary disease, or COPD, among disabled adults covered by Medicaid has improved with the expansion of a new health care program in Texas over the last decade. [More]
First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Researchers at the Johns Hopkins University School of Medicine, Johns Hopkins University Department of Chemical and Biomolecular Engineering, and Federal University of Rio de Janeiro in Brazil have designed a DNA-loaded nanoparticle that can pass through the mucus barrier covering conducting airways of lung tissue — proving the concept, they say, that therapeutic genes may one day be delivered directly to the lungs to the levels sufficient to treat cystic fibrosis (CF), chronic obstructive pulmonary disease, asthma and other life-threatening lung diseases. [More]
New national survey finds lack of COPD knowledge among patients

New national survey finds lack of COPD knowledge among patients

In a new national survey of chronic obstructive pulmonary disease (COPD) patients, Health Union reveals a surprising lack of awareness of risk factors and knowledge of diagnosis stage among patients. Results demonstrate a severe impact on quality of life, employment, and ability to afford treatment. [More]
Researchers uncover groundbreaking evidence for developing vaccine to prevent middle ear infections

Researchers uncover groundbreaking evidence for developing vaccine to prevent middle ear infections

Researchers from Griffith University's Institute for Glycomics, together with the Nationwide Children's Hospital in Ohio, have uncovered groundbreaking evidence to help vaccine developers prevent middle ear infections. [More]

Factors linked with increased risk of falling identified in patients with COPD

In a recent year-long study, 40% of patients with chronic obstructive pulmonary disease (COPD) experienced falls, with more than 75% of these falling multiple times. [More]
COPD risk may occur during childhood and adolescence

COPD risk may occur during childhood and adolescence

Chronic obstructive pulmonary disease (COPD) is one of most common causes of death in the world today - active smoking accounting for approx. 85% of all cases. Yet ground-breaking research from the University of Copenhagen indicates that accelerated decline of lung function is not a prerequisite for COPD. [More]
Evidence-based initiative aims to prevent avoidable hospital readmissions

Evidence-based initiative aims to prevent avoidable hospital readmissions

A statewide effort led by key stakeholders in South Carolina successfully organized and implemented an evidence-based initiative aimed at improving the quality of healthcare transitions after hospital discharge to prevent avoidable readmissions. [More]
New portable system can produce life-saving NO from air by means of electrical spark

New portable system can produce life-saving NO from air by means of electrical spark

Treatment with inhaled nitric oxide (NO) has proven to be life saving in newborns, children and adults with several dangerous conditions, but the availability of the treatment has been limited by the size, weight and complexity of equipment needed to administer the gas and the therapy's high price. [More]
Boehringer Ingelheim’s Spiolto Respimat approved for COPD treatment in first European countries

Boehringer Ingelheim’s Spiolto Respimat approved for COPD treatment in first European countries

Boehringer Ingelheim today announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European countries. Spiolto Respimat is a once-daily maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). [More]
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
Long-term smokers and ex-smokers have respiratory-related impairments

Long-term smokers and ex-smokers have respiratory-related impairments

More than half of long-term smokers and ex-smokers who are considered disease-free because they passed lung-function tests have respiratory-related impairments when more closely evaluated with lung imaging, walking and quality-of-life tests. Many of those people likely have the earliest stages of chronic obstructive pulmonary disease, an incurable progressive disease (COPD) that is the third leading cause of death in the United States. [More]

Helmholtz Zentrum München scientists investigating molecular causes of COPD

At present, there is a lack of effective treatments that target the causes of chronic obstructive pulmonary disease (COPD). Scientists of the Comprehensive Pneumology Center at Helmholtz Zentrum München are therefore investigating the molecular causes of COPD in order to intervene specifically. [More]
Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF). [More]
Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures. [More]
Advertisement